Results 181 to 190 of about 33,041 (261)

An inducible caspase 9 safety switch for T-cell therapy

, 2005
Pule, MA, Heslop, HE, Vanin, EF, Spencer, DM, Straathof, KC, Rooney, CM, Brenner, MK, Yotnda, P, Dotti, G   +8 more
core  

BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Nadia Al Haddad, Eugene Brailovski, Jacqueline Dela‐Pena, Melinda Cook, Michael Rosenzweig, Heather Jolie Landau   +5 more
wiley   +1 more source

Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting. [PDF]

Mol Oncol
Gonzalez-Garcia P, Moares N, Yi-He W, Luna-Espejo R, Fernandez-Cisnal R, Ocaña-Cuesta J, Muñoz-Miranda JP, Gabucio A, Fernandez-Ponce CM, Garcia-Cozar F.   +9 more
europepmc   +1 more source

Spinal Implant–Associated Infection in Type 2 and Type 1 Diabetes: Phenotype‐Specific Inflammatory Features and Therapeutic Response to Semaglutide

JOR SPINE, Volume 9, Issue 2, June 2026.
ABSTRACT Background Diabetes mellitus (DM) is a major risk factor for postoperative infection and wound complications in spine surgery, yet distinctions between Type 2 (T2DM) and Type 1 (T1DM) pathophysiology are rarely addressed. This study compares infectious burden, wound healing, and immune response among a murine model of spinal implant‐associated
Thomas E. Olson, Trevor S. Lloyd, Christopher D. Hamad, Rene F. Chun, Joshua Wiener, Autreen Golzar, Joshua Mehany, Soroush Shahamatdar, Andrew Kittredge, Lauren Pearce, Kevin P. Francis, Farres Obeidin, Langston T. Holly, Michael R. Yeaman, John S. Adams, Nicholas M. Bernthal, William L. Sheppard   +16 more
wiley   +1 more source

Impact of Anti-CD20 Therapies on Cytokine, Chemokine and Adhesion Molecule Dynamics in Multiple Sclerosis: A Narrative Review. [PDF]

Neurol Ther
Messner M, Mitterwallner JM, Unterhofer M, Wipfler P, Harrer A, Moser T.   +5 more
europepmc   +1 more source

Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies

MedComm, Volume 7, Issue 6, June 2026.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by unleashing antitumor immunity. This review comprehensively examines the molecular mechanisms underlying key immune checkpoints—including PD‐1/PD‐L1, CTLA‐4, and TIM‐3—and their clinical applications.
Qintao Ge, Liu Yu, Jiahe Lu, Aihetaimujiang Anwaier, Xiyue Xiao, Yonghao Chen, Dingwei Ye, Hailiang Zhang, Wenhao Xu, Wenbin Dai   +9 more
wiley   +1 more source

Immune cells and rheumatic heart disease: A 2-sample and Bayesian weighted Mendelian randomization study. [PDF]

Medicine (Baltimore)
Xue S, Jiang H, Liu C, Zhou Y.
europepmc   +1 more source

Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series

MedComm – Oncology, Volume 5, Issue 2, June 2026.
In the GLOHRT‐01 study, the first four enrolled patients with relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) and high tumor burden achieved complete metabolic response (CMR) following combination therapy with hypofractionated radiotherapy (HRT) and glofitamab.
Jingshu Meng, Qiuhui Li, Fang Zhu, Lu Zhou, Xinxiu Liu, Tao Liu, Chunxia Qin, Huaxiong Pan, Baixin Ye, Liling Zhang   +9 more
wiley   +1 more source

A Customizable Tyramide Signal Amplification-Based Multiplex Immunofluorescence Protocol for FFPE Tissues. [PDF]

Curr Issues Mol Biol
Sheng W, Mohiuddin TM, Zhang C, Al-Rawe M, Konrad L, Wagner S, Zeppernick F, Meinhold-Heerlein I, Hussain AF.   +8 more
europepmc   +1 more source